Calls
1
u/ED209F
Reddit r/ValueInvesting
Win Rate
0.0%
return
-28.5%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 12
$60.60
-28.5%
The author claims investors are underweight Novo Nordisk, citing company guidance that oral GLP-1 pills will capture over a third of the obesity market by 2030 and that the pill market is bigger than initially thought. Novo is prioritizing a U.S. launch to avoid past supply issues, which the author implies supports the growth thesis. The catalyst is the 2030 pill market opportunity and U.S. launch execution.
GLP-1 / Obesity
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/ED209F has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: NVO.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
